DR. CHARLES WADE TAYLOR M.D. NPI 1003859679

NPI Details

DR. Charles Wade Taylor, M.D. is a hematology and oncology internal medicine in Tulsa, OK with 44 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Charles Wade Taylor, M.D. NPI is 1003859679. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE
Graduation Year:1982

The provider's business location address is:

12697 E 51ST ST
TULSA, OK
ZIP 74146-236
Phone: (918) 505-3200
Fax: (918) 505-3253

The NPI 1003859679 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of chest with contrast (HCPCS:71260)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Unclassified drugs (HCPCS:J3490)
• Blood creatinine level (HCPCS:82565)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Collection of blood sample from implanted device (HCPCS:36591)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Red blood count, automated test (HCPCS:85045)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Drawing of blood for a medical problem (HCPCS:99195)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Nuclear medicine study of bone and/or joint whole body (HCPCS:78306)
• Nuclear medicine study of heart pumping function by labeling red blood cells with measurement of internal blood volume ejected with every beat over multiple cycles (HCPCS:78472)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9561)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9560)
• X-ray of chest, 2 views (HCPCS:71046)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)

The enumeration date for this NPI number is 6/13/2006 and was last updated on 5/1/2015.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.